Terms: = Kidney tumors AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790
11 results:
1. Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.
Pan D; Zhao W; Jiang Q; Yin C; He H; Liao L; Ye J; Dai M
Leuk Lymphoma; 2023 Apr; 64(4):856-864. PubMed ID: 36905177
[TBL] [Abstract] [Full Text] [Related]
2. tet2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract] [Full Text] [Related]
3. Ascorbic acid induced tet2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma.
Peng D; He A; He S; Ge G; Wang S; Ci W; Li X; Xia D; Zhou L
Int J Biol Sci; 2022; 18(3):995-1007. PubMed ID: 35173532
[TBL] [Abstract] [Full Text] [Related]
4. Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer.
Aggarwal RK; Luchtel RA; Machha V; Tischer A; Zou Y; Pradhan K; Ashai N; Ramachandra N; Albanese JM; Yang JI; Wang X; Aluri S; Gordon S; Aboumohamed A; Gartrell BA; Hafizi S; Pullman J; Shenoy N
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34551979
[TBL] [Abstract] [Full Text] [Related]
5. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease.
Dawoud AAZ; Gilbert RD; Tapper WJ; Cross NCP
Leukemia; 2022 Feb; 36(2):507-515. PubMed ID: 34413458
[TBL] [Abstract] [Full Text] [Related]
6. tet2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract] [Full Text] [Related]
7. Primary renal well-differentiated neuroendocrine tumour (carcinoid): next-generation sequencing study of 11 cases.
Pivovarcikova K; Agaimy A; Martinek P; Alaghehbandan R; Perez-Montiel D; Alvarado-Cabrero I; Rogala J; Kuroda N; Rychly B; Gasparov S; Michalova K; Michal M; Hora M; Pitra T; Tuckova I; Laciok S; Mareckova J; Hes O
Histopathology; 2019 Jul; 75(1):104-117. PubMed ID: 30851202
[TBL] [Abstract] [Full Text] [Related]
8. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
[TBL] [Abstract] [Full Text] [Related]
9. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma.
Shenoy N; Bhagat TD; Cheville J; Lohse C; Bhattacharyya S; Tischer A; Machha V; Gordon-Mitchell S; Choudhary G; Wong LF; Gross L; Ressigue E; Leibovich B; Boorjian SA; Steidl U; Wu X; Pradhan K; Gartrell B; Agarwal B; Pagliaro L; Suzuki M; Greally JM; Rakheja D; Thompson RH; Susztak K; Witzig T; Zou Y; Verma A
J Clin Invest; 2019 Mar; 129(4):1612-1625. PubMed ID: 30702441
[TBL] [Abstract] [Full Text] [Related]
10. tet2 binds the androgen receptor and loss is associated with prostate cancer.
Nickerson ML; Das S; Im KM; Turan S; Berndt SI; Li H; Lou H; Brodie SA; Billaud JN; Zhang T; Bouk AJ; Butcher D; Wang Z; Sun L; Misner K; Tan W; Esnakula A; Esposito D; Huang WY; Hoover RN; Tucker MA; Keller JR; Boland J; Brown K; Anderson SK; Moore LE; Isaacs WB; Chanock SJ; Yeager M; Dean M; Andresson T
Oncogene; 2017 Apr; 36(15):2172-2183. PubMed ID: 27819678
[TBL] [Abstract] [Full Text] [Related]
11. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.
Nickerson ML; Im KM; Misner KJ; Tan W; Lou H; Gold B; Wells DW; Bravo HC; Fredrikson KM; Harkins TT; Milos P; Zbar B; Linehan WM; Yeager M; Andresson T; Dean M; Bova GS
Hum Mutat; 2013 Sep; 34(9):1231-41. PubMed ID: 23636849
[TBL] [Abstract] [Full Text] [Related]
